The inclusion of targeted therapies such as Trastuzumab, Pertuzumab, and Pembrolizumab, especially in human epidermal growth factor receptor 2 (HER2)-positive or triple-negative BC, along with anthracycline and taxane-based chemotherapy regimens, has demonstrated significant potential in eradicating nodal involvement in approximately 50–75% of cases, depending on the biological subtype of BC [21,22,23,24,25]. The gene discussed is ERBB2; the disease is breast cancer.